Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698568 · ClinicalTrials.gov registry record · Phase 3
Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,460
- Enrollment target
NCT00698568: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00698568 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 7,460 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (866% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00698568, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,460 participants
- Enrollment target
Study Summary
This study will evaluate, versus a placebo, the safety of Herpes simplex candidate vaccine with adjuvant in initially HSV seropositive or seronegative subjects who have no genital herpes disease.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Herpes simplex candidate vaccine- adjuvanted GSK 208141
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,460 participants |
| Start Date | 1996-10 |
| Est. Completion | 1999-04 |
| Phase | Phase 3 |
What the finished NCT00698568 record still lists
NCT00698568 is an interventional study that assigns participants to a tested intervention. Its 7,460 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (866% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00698568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00698568 about?
NCT00698568 is a clinical study titled "Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects". This study will evaluate, versus a placebo, the safety of Herpes simplex candidate vaccine with adjuvant in initially HSV seropositive or seronegative subjects who have no genital herpes disease.
What is the current status of trial NCT00698568?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,460 participants. The study started on 1996-10. Estimated completion is 1999-04.
What interventions are being tested in trial NCT00698568?
The interventions under investigation include: Placebo (BIOLOGICAL), Herpes simplex candidate vaccine- adjuvanted GSK 208141 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00698568?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00698568's enrollment target sits among peer trials
7,460 34th of 2000 higher than 1,967 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
- NCT05199701 · 7,500 participants · NA
Prospective Case Collection Study for New Mammography Technologies
- NCT06112418 · 7,500 participants · NA
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia